The brk gene encodes a non-receptor tyrosine kinase that has been found to be overexpressed in approximately two thirds of breast tumours. Using a yeast two-hybrid based screen, we have cloned cDNAs encoding a novel protein, BKS, that is a substrate for the kinase activity of BRK and has the characteristics of an adaptor protein. BKS possesses an N-terminal PH-like domain followed by an SH2-like domain. In co-transfection experiments, high levels of phosphotyrosine were observed on BKS and BRK was found to be associated with BKS, both of which were dependent on the catalytic activity of BRK. The phosphorylation of and association with BKS by BRK was also dependent on the SH2-like domain present within BKS. In addition, BKS recruited an unidenti®ed 100 kDa protein that was also phosphorylated on tyrosine residues in the presence of BRK. We have determined that the BKS protein is expressed in most adult human tissues. Oncogene (2000) 19, 4273 ± 4282.
Introduction
Tyrosine kinases are important regulators of proliferative, dierentiative and apoptotic signals. Perturbation of their normal cellular function, either by mutation, rearrangement or overexpression, often occurs in the development of human tumours (reviewed Kolibaba and Druker, 1997) . Germline mutations in the receptor tyrosine kinase gene, ret, have been found in familial medullary thyroid carcinoma and multiple endocrine neoplasias types 2a and 2b (reviewed van Heyningen, 1994) . More recently, activating mutations in src have been found in a subset of advanced human colon carcinomas (Irby et al., 1999) . Overexpression of members of the epidermal growth factor receptor (EGFR) family has frequently been observed in human breast carcinomas. Ampli®ca-tion of the c-erbB-2 gene has been detected in approximately 15 ± 20% of cases (Slamon et al., 1987; Van de Vijver et al., 1988) . Moreover, elevated expression of c-erbB-2 mRNA or protein has been observed in 20 ± 30% of primary breast cancers and has been correlated with poor prognosis (Slamon et al., 1987 (Slamon et al., , 1989 Gullick et al., 1991; Paterson et al., 1991; Gusterson et al., 1992) .
The brk gene, which encodes a non-receptor tyrosine kinase, was identi®ed while examining protein tyrosine kinase (PTK) expression in human metastatic breast tumours (Mitchell et al., 1994) ; and was found to be overexpressed in a high proportion of breast carcinomas . Expression of BRK in mammary epithelial cells potentiates both their anchorage independent proliferation and their mitogenic response to epidermal growth factor (Kamalati et al., 1996) , implying a role for BRK in growth regulation and potentially, tumour development. The predicted BRK protein contains SH3, SH2 and PTK catalytic domains, similar to SRC, and although BRK shows the highest sequence similarity to SRC family members, there are several key structural, regulatory and evolutionary dierences. First, BRK lacks an N-terminal extension and consensus sequence for fatty acylation and membrane association. Secondly, although BRK has a Cterminal tyrosine (Y447) analogous to the regulatory tyrosine in SRC, it would appear that Y447 is not involved in negatively regulating its catalytic activity. Negative regulation of SRC kinase activity is mediated through phosphorylation of this C-terminal tyrosine (Tyr 527), and results from an interaction of phosphorylated Tyr 527 with the amino terminal SH2 domain (Xu et al., 1997; Sicheri et al., 1997) . In the case of SRC and related proteins, this regulatory tyrosine can be phosphorylated by the non-receptor PTK CSK Okada et al., 1991; Bergman et al., 1992) . Unlike SRC kinases in which mutation of Tyr 527 (or its equivalent) to Phe results in deregulated kinase activity and increased transforming ability (Kmiecik and Shalloway, 1987; Piwnnica-Worms et al., 1987; Cartwright et al., 1987; Amrein and Sefton, 1988; Abraham and Veilette, 1990; Zeigler et al., 1989; Davidson et al., 1994) , mutation of Tyr 447 to Phe signi®cantly decreases BRK's capacity to induce anchorage independent growth (Kamalati et al., 1996) . Thirdly, although BRK shows the highest sequence similarity to the SRC family of non-receptor PTKs its genomic structure is quite distinct suggesting evolutionary divergence (Mitchell et al., 1997) .
As very little is known with regard to the signalling pathways BRK is involved in, we have sought to identify proteins that interact with BRK. Given the key dierences between BRK and members of the SRC family of non-receptor PTKs we thought it unlikely that they would share common interacting partners and therefore have attempted to identify proteins that BRK interacts with using the yeast two-hybrid screen-ing system. Here we present the identi®cation and characterization of such a molecule.
Results

Isolation of cDNAs encoding BRK interacting proteins
In order to identify proteins that interact with BRK, a yeast strain was engineered to express the entire brk open reading frame as a GAL4 DNA binding domain fusion protein. This was used to screen a normal breast two-hybrid cDNA library. From approximately one million transformants, four clones (NB 7, 25, 27 and 28) were isolated that encoded proteins interacting speci®cally with BRK. Three of them (NB 25, 27 and 28, Figure 2a) corresponded to a novel mRNA we called bks. The cDNA inserts of clones NB25 and 27 were identical and were approximately 1.3 kb in length, while clone NB 28 had an additional 87 bp of 5' sequence and an insert of 138 bp near the 3' end of the cDNA. All three clones had open reading frames (ORF) extending nearly the entire length of the cDNAs which were all in frame with the GAL4 activation domain encoded by the yeast two-hybrid expression vector. The other clone, NB7, corresponded to an alternative reading frame of a rearranged immunoglobulin gene and probably represented a false positive.
To further verify that bks cDNAs encoded a BRK interacting protein, a bacterial expression construct was made with the ORF of clone NB27 fused in frame with Glutathione S transferase (GST). Anity puri®ed GST fusion (BKS) protein and GST bound to glutathione sepharose were mixed with lysates prepared from the human breast luminal epithelial cell line Hb4a engineered to stably express BRK (Kamalati et al., 1996) . Using a monoclonal antibody speci®c for BRK on Western blots of the washed beads, BRK (52 kDa) was found to associate speci®-cally with the BKS fusion protein (Figure 1a) .
In order to ascertain whether we had isolated cDNAs corresponding to the entire bks mRNA we screened Northern blots and isolated more bks cDNAs using a radiolabelled 0.5 kb probe from the 5' end of the cDNAs (P1, Figure 2a ). bks transcripts of approximately 1.5 ± 1.6 kb were detected in CAL51, T-47D and MCF7 breast cancer cell line poly(A) + mRNAs and total RNA isolated from the human breast luminal cell line Hb4a and puri®ed human breast luminal and myoepithelial cells (Figure 1b) . Three independent bks cDNAs (T9, 13 and 14) were isolated from a T-47D cell line cDNA library which were 1.5, 1.5 and 1.4 kb in length respectively (Figure 2a ). Clones T9 and 13 both contained the 138 bp insert present in NB28. The longest bks cDNA NB28 contained an ORF of 1347 bp starting with a consensus sequence for translational initiation (Kozak, 1989) . The ORF was preceded by a 5' sequence of 58 bp that did not contain any in-frame stop codons. cDNAs without the 3' insert contain an ORF of 1209 bp. In vitro translation in rabbit reticulocyte lysates using transcripts generated from clone T9 resulted in the synthesis of a protein with the mobility of 62 and 64 kDa (data not shown). These experiments indicated that the predicted start codon in the bks cDNAs could act as an initiation site for translation and, therefore, that the cDNAs isolated most likely contained the complete bks coding region.
Searching of the non-redundant GenBank nucleotide databases using Gapped BLAST (Altshul et al., 1997) identi®ed that the 138 bp insert showed strong sequence identity to members of the Alu-Sq and Alu-Sx subfamily (94% and 93% over 108 bp respectively). It is worthy of note that there is a consensus 5' splice donor sequence at the 5' end of the insert (bold Figure 2c) . In addition, searching of the non-redundant database of GenBank expressed sequence tag (EST) nucleotide entries identi®ed a large number bks ESTs. Thirty-two of these bks ESTs have been aligned and assigned a UniGene number Hs. 194385, which has been mapped to chromosome 19 interval pTel-D19S413. + RNA (0.5 mg) and of total RNA (10 mg) isolated from the normal breast cell line Hb4a and from puri®ed breast epithelial cells. The blot was hybridized to 0.5 kb radiolabelled bks cDNA probe P1 ( Figure  2a ) and to a radiolabelled GAPDH cDNA to control for RNA loading respectively with predicted molecular weights of 50 and 45 kDa. The nucleotide sequence and amino acid translation of the shorter bks cDNA are shown in Figure 2b with the nucleotide and amino acid sequence of the additional 138 bp insert present in clones NB28, T9 and 13 shown in Figure 2c . Overall the percentage of proline residues within BKS is high at 11% and might explain the retarded mobility of in vitro translated BKS in polyacrylamide gels. Comparing BKS with the Prosite database identi®ed two particular domains of interest within the BKS amino acid sequence. Between residues 19 ± 118 a putative PH domain was identi®ed. This homology was not detected using Gapped BLAST but was found when BKS was aligned against PH domain pro®les. BKS contains a large proportion of the highly conserved residues and the invariant tryptophan ( Figure 3b ) (Haslam et al., 1993; Mayer et al., 1993; Musacchio et al., 1993 ). An SH2 like domain was predicted to be located between residues 156 ± 245 in BKS (Figures 2b and 3c ). The predicted SH2 like domain shows high conservation of the invariant residues present in characterized SH2 domains. However, the FLVRS motif surrounding the invariant arginine present in the phosphotyrosine binding pocket, is LLLRP in BKS. This SH2 domain like region of BKS was the only one to show signi®cant homology to other proteins. The predicted SH2 domain of BKS showed overall amino acid identities to the SH2 domains of rat phospholipase C gamma 2 (30%), Drosophila Src64 (34%), mouse Srm (29%), mouse BLK (28%) and mouse PTP-2C (27%) ( Figure  3c ). In addition, searching the Prosite database identi®ed two predicted tyrosine phosphorylation sites at positions 36 and 213, with three other tyrosine residues in an acidic context (250, 310 and 322) which may also be potential phosphorylation sites. Within the proline rich C-terminus of BKS two sequences (KLPPLPP and KKLPKPP) were identi®ed as putative class I SH3 binding sites and one sequence (LPKPPAK) was identi®ed as a putative class II SH3 
Expression of BKS in human tissues and mammary-derived cell lines
Using puri®ed BKS-GST fusion protein, we raised a polyclonal antiserum against BKS. Anity puri®ed antiserum was used on Western blots of lysates from normal and breast tumour cell lines including ones we have identi®ed that express bks transcripts. Immunoreactive proteins with mobilities in the size range of 60 ± 62 kDa were detected in lysates from two normal breast luminal cell lines Hb4a and b and in several breast tumour lines including T-47D and MCF-7 (Figure 4a ). To test the speci®city of the antiserum We next examined BKS expression on Western blots of lysates made from a series of normal human tissues. BKS expression was detected in most of the tissues tested, with the exception of skeletal muscle ( Figure  4c) . A judgement can not currently be made as to whether BKS is expressed in oesophagus or bone marrow, due to the poor quality of the protein extracts obtained from these tissue sources. Higher mobility immunoreactive proteins were detected in lysates from stomach, spleen and sub-maxillary gland.
BKS interacts with and is a substrate for BRK
In order to investigate the interaction between BRK and BKS, wild type BRK or kinase inactive BRK K219M (Kamalati et al., 1996) expression constructs were cotransfected into 293 cells with a BKS expression construct. Western blots of whole cell lysates, using anti-phosphotyrosine antibodies, demonstrated that when kinase active BRK and BKS were co-expressed this resulted in the presence of additional phosphoproteins in the size range of 50 ± 64 kDa (Figure 5a ). To ascertain whether any of the additional phosphoproteins were BKS, epitope tagged BKS was co-expressed with BRK. High levels of phosphotyrosine were detected on anity precipitated BKS from cells coexpressing kinase active BRK. Associated with this, BKS acquired a retarded mobility in SDS ± PAGE (Figure 5b ). In addition to high levels of phosphotyrosine on BKS a 100 kDa phosphoprotein co-precipitated with BKS. The phosphotyrosine on the 100 kDa BKS associated protein was dependent on the coexpression of kinase active BRK.
We next looked to see whether BRK was associated with BKS. Wild type BRK was detected with BKS, on Western blots of the anity precipitates, in a BKS dependent manner, whereas kinase inactive BRK was barely detectable (Figure 5b ). To assess whether any of the other structural domains of BRK were required for the interaction with and phosphorylation of BKS, constructs expressing SH3 domain mutants and an SH2 domain mutant were generated. For the SH3 domain, mutations were made in BRK corresponding to tryptophan ). These two mutations were analogous to tryptophan 118 -alanine and tyrosine 136 -alanine mutations in SRC which have been shown to abolish the ability of the SRC SH3 domain to participate in intramolecular regulation and to bind heterologous binding partners such as Sam68 and p85 in vitro (Erpel et al., 1995) . Arginine 105 was mutated to leucine (brk R105L ) in the BRK SH2 domain, which corresponded to arginine 175 in v-SRC which is the invariant residue present in the FLVRS motif and forms part of the phosphotyrosine recognition site. R 175 in v-SRC makes contact with the phosphate group on the tyrosine residue (Waksman et al., 1992) and mutation to leucine abrogates phosphotyrosine binding (Bibbins et al., 1993) .
Co-expression of BRK with a mutant SH3 domain together with BKS resulted in a reduction in the phosphotyrosine levels on BKS and associated p100, particularly with brk W44A , when compared with wild type BRK (Figure 5b ). The reduction of phosphotyrosine levels on BKS in the presence of this mutant was not paralleled by a reduction in the levels of BRK associated with BKS in the anity precipitates. The other BRK SH3 mutant (brk Y66A ) had a lesser eect on the phosphotyrosine levels on BKS and p100 compared to wild type BRK, but signi®cantly less was associated with BKS. When BRK with a mutated SH2 domain was co-expressed with BKS, again a small reduction of phosphotyrosine levels was observed on BKS together with p100 (Figure 5b ). The levels of this mutant form of BRK associated with BKS were substantially reduced, with all of the BRK R105L in this complex having a retarded mobility. This change in mobility was mirrored on Western blots of the cell lysates, where a small proportion of BRK had a similar retarded mobility only when co-expressed with BKS. Please note that occasionally we observed a negligible amount of non-speci®c binding of BRK to the Ni agarose beads (compare lanes 1 Figure 5b,c) .
Requirement of the SH2 like domain of BKS for interaction with BRK
It appears that phosphorylation of BKS is not extensively dependent on either the SH2 or SH3 domains of BRK, but is dependent on an active kinase domain of BRK. We then examined the role of the SH2-like domain of BKS on the phosphorylation by and association with BRK. The invariant arginine residue that would be predicted to be central to phosphotyrosine binding was mutated to leucine in BKS (bks R178L ). When this mutant was co-expressed with kinase active BRK, very little phosphotyrosine was detected on Western blots of anity precipitated BKS compared to wild type BKS expressed with BRK ( Figure 5c ). In addition, very little BRK was associated with the SH2 mutant form of BKS in the anity precipitates. These observations were not due to dierences of BKS levels in the precipitation or varying expression levels of BRK. Along with the large reduction of the levels of phosphotyrosine on BKS R178L very little phosphorylated p100 was detected ( Figure  5c ). We do not know, however, whether this is a result of changes in levels of phosphotyrosine or reduction in the amount of BKS associated p100.
Discussion
Using a yeast two-hybrid assay screen we have identi®ed and characterized cDNAs that encode a novel protein that interacts with the non-receptor tyrosine kinase BRK. The cDNAs isolated encode proteins of 403 (BKS-s) and 449 (BKS-1) amino acids with SDS ± PAGE mobilities of 60 ± 62 and 62 ± 64 kDa respectively. Both bks-s (T14) and bks-1 cDNAs (NB28, T9, T13) each contain only one open reading frame capable of producing proteins of these sizes, with ) on their own or together with BRK. Epitope tagged BKS was precipitated from RIPA lysates using Ni agarose. Western blots of the Ni agarose precipitates were probed with the anti-phosphotyrosine antibody, PY20 (upper panel), the anti-BRK monoclonal antibody (2nd from top) and the anti-BKS polyclonal antibody (2nd from bottom). A Western blot of RIPA cell lysates was probed with the anti-BRK monoclonal antibody (lower panel). The mobilities of the molecular weight markers are shown in kDa only one likely translational start codon. Our observation of two protein products derived from the bks-s and bks-1 cDNAs in vivo (Figure 4b ) cannot be explained by the use of a non-ATG translation initiation codon as anity precipitates of N-terminally epitope tagged BKS-s also have mobilities of 60 and 62 kDa (Figure 5b ) and, therefore, must have identical N-termini. These forms of BKS may be generated by post-translational modi®cation or cleavage at the Cterminus of the primary bks-s translation product. These possibilities are currently under investigation.
The longer bks-1 transcript contains part of an Alu repeat within its open reading frame that is translated into the mature protein. This may be due to alternative splicing of the primary bks cDNA as a result of the use of an internal 5' splice donor site within an intron. It is not clear whether the protein encoded by this isoform is expressed in vivo. Most of the breast carcinoma cells that expressed BKS contained a species that comigrated with the slowest-migrating product of the bks-s cDNA (compare Figure 4a,b) . A screen of human expressed sequence tag (EST) databases revealed that, among approximately 30 informative ESTs, bks-s like transcripts were approximately ®vefold more abundant than bks-1 like transcripts (unpublished). However, we have shown that the region of dierence in the amino acid sequences of the BKS-s and BKS-1 proteins is not required for the interaction with BRK. Alternatively, the dierence in BKS mobilities may be due to post translational modi®cation. Our studies have demonstrated that tyrosine phosphorylation of BKS retards its mobility in SDS ± PAGE and therefore it would be of interest to see whether dierential tyrosine phosphorylation is responsible for BKS having dierent mobilities. BKS was found to be expressed in a large proportion of human tissues. A protein of higher mobility than those derived from bks-s or bks-1 cDNAs was detected in the protein sample derived from stomach. The nature of this species is unknown, however a screen of human EST databases suggested that smaller BKS proteins than those described here could be derived by alternative mRNA splicing (unpublished).
The domain structure of BKS along with several potential tyrosine phophorylation sites and SH3 domain interaction sites would indicate that BKS has the characteristics of an adaptor-like protein which may be capable of interacting with several other signalling molecules. The N-terminus of BKS contains a PH-like domain. The PH domain was initially identi®ed as a region of sequence homology, of approximately 110 amino acids, that is duplicated in pleckstrin, the major substrate of protein kinase C (Mayer et al., 1993; Haslam et al., 1993) . Although their amino acid sequences are diverse, only a single tryptophan being invariant within the 100 ± 110 residues (Musacchio et al., 1993; Gibson et al., 1994) , PH domains share a common structure (reviewed Blomberg et al., 1999) . Many of the proteins that contain PH domains play a role in cellular signalling or cytoskeletal organization that requires association with cell membranes and it is now generally accepted that many PH domains mediate protein-phospholipid interactions. In the case of protein kinase B (PKB), considerable evidence is provided that its PH domain along with the PH domain of phosphoinositidedependent protein kinase (PDK) bind the products of phosphatidylinositol 3-kinase (PI3-K) serving to localise and activate this enzyme complex (reviewed Coer et al., 1998; Shepherd et al., 1998) . In the case of BKS it would therefore be of interest to determine whether its PH domain is important for its interaction with BRK or enables signalling downstream of BRK to occur. With this in mind, we generated a BKS PH domain mutant (Y36S) analogous to the mutation in the PH domain (F25S) of the tyrosine kinase, BTK, found in patients with X-linked agammaglobulinemia. The analogous residue in the PH domain of PLC d binds the one phosphate residue in inositol-(1,4,5)-triphosphate (Ferguson et al., 1995) and its mutation in BTK has been shown to result in dramatic reduction of inositol-(1,3,4,5)-tetrakisphosphate binding (Fukada et al., 1996) . However, expression of BKS (Y36S) in 293 cells was very poor and we were, therefore, unable to interpret the results of our co-transfection experiments (data not shown).
Adjacent to the PH domain in BKS is an SH2-like domain. SH2 domains play a pivotal role in signal transduction processes by binding sites of tyrosine phosphorylation (reviewed Schahausen, 1995) . These highly conserved modular regions of approximately 100 amino acids have a similar overall topology consisting of a large central b-sheet and an associated smaller b-sheet,¯anked by two a-helices. The binding site for the pTyr involves a network of charge-charge and hydrogen bonding interactions between residues of the SH2 domain and the phosphate oxygen and aromatic p electrons of the pTyr ring. As well as the pTyr the peptide sequence C-terminal to the residue is important for the speci®city of the interaction. The BKS SH2 like domain does not have as high a sequence similarity as that seen between known SH2 domains. This is most notable in the region of the FLVRS motif, which in BKS is LLLRP. However, BKS does contain many highly conserved residues and in particular the invariant arginine (LLLRP), which directly binds the phosphate on the tyrosine. As will be discussed later, this region may indeed function as a phosphotyrosine binding domain.
When co-expressed with BRK, a high level of phosphotyrosine was seen on BKS, along with it having a retarded mobility in SDS ± PAGE. In addition, BRK was readily detectable in BKS anity precipitates. The high levels of phosphotyrosine on BKS were dependent on the catalytic activity of BRK which in turn was required for its association with BKS, suggesting that BRK may directly phosphorylate BKS. Attempts at mapping the phosphorylation sites within BKS by in vitro mutagenesis have shown that there are at least two sites of tyrosine phosphorylation, one of which is Y250 (data not shown). Mutation of either the SH2 or SH3 domain of BRK did not have a major eect on the ability of BRK to phosphorylate BKS, as seen by anti-phosphotyrosine Western blots and by the levels of retarded BKS, although a reduction in the levels of co-precipitating BRK was seen with the SH3 domain mutant, BRK
Y66A
, and the SH2 domain mutant. This may be due to the fact that these domains of BRK are important for stabilizing BRK/BKS complexes either directly or by recruiting other regulatory proteins. However, mutation of the SH2 like domain within BKS dramatically reduced the levels of phosphotyrosine on BKS and the levels of associated BRK. One explanation for this is that the SH2 domain within BKS is important for interacting with a phosphorylated tyrosine residue within BRK and therefore, this association brings tyrosine residues within BKS in close proximity with the catalytic domain of BRK. One might speculate that, as the catalytic activity of BRK is required for the association with BKS, the SH2 domain of BKS interacts with an autophosphorylated tyrosine within BRK. It is worthy of note that mutation of the BRK C-terminal tyrosine does not aect the ability of BRK to phosphorylate and associate with BKS (data not shown).
In addition to the high levels of phosphotyrosine seen on BKS in the presence of BRK, a 100 kDa phosphoprotein co-precipitates with BKS. Using the kinase inactive mutant of BRK and the SH2 domain mutant of BKS we have shown that the phosphotyrosine detected on p100 is dependent on the catalytic activity of BRK and its ability to interact with BKS. The presence of phosphorylated p100 does not require a functional SH2 or SH3 domain within BRK. However, we do not know whether unphosphorylated p100 is associated with either BRK or BKS, or if the association with and phosphorylation of BKS by BRK is required for p100 recruitment. Resolution of this question awaits the identi®cation of p100. It is possible that p100 is also a tyrosine kinase that is activated in the presence of BKS and BRK or that p100 is a BRK substrate. With this in mind, using Western blots of the BKS anity precipitates, we have looked to see whether p100 is a known protein which has been shown to undergo tyrosine phosphorylation. p100 is not one of the following; eps8 (Fazioli et al., 1993) , a and b catenin, pp120 (reviewed Daniel and Reynolds, 1997) or Dynamin (Baron et al., 1998) .
The functional consequences of the BKS-BRK interaction remain to be clari®ed. We have not detected any change in the kinase activity of BRK due to an association with BKS, nor have we detected a change in the sub-cellular localization of BRK due to the coexpression of BKS (unpublished). It may be that the role of BKS is in mediating the proximity of BRK with speci®c regulators or substrates, and p100 may be one such substrate. Alternatively, BKS may indeed regulate the sub-cellular localization of BRK, but in response to particular stimuli such as the binding of phospholipids to the PH-like domain of BKS. This area of research is clearly a high priority for future investigations.
During the preparation of this manuscript Ohya et al. (1999) reported the identi®cation of BRDG1, a docking protein which is phosphorylated by TEC in response to B-cell receptor activation. BRDG1 has a very similar structure to BKS with several candidate tyrosine phosphorylation sites and has 38% sequence identity across the PH and SH2-like domains. BRDG1 and BKS, therefore, may represent members of a new family of docking proteins phosphorylated by nonreceptor tyrosine kinases. We have found BKS expression to be widespread, in particular it was detected in all but one of the human tissues tested. Given that expression of BRK and its murine homolog, SIK, is limited to regions of the gut and skin (PJ Mitchell unpublished data; Vasioukhin et al., 1995) BKS is likely to be involved in signalling by related tyrosine kinases in dierent tissues. Future work will focus on the role BKS plays in tyrosine kinase signalling pathways.
Materials and methods
Yeast two-hybrid screen and cDNA cloning
The cDNA sequence encoding the full-length human BRK was cloned into pYTH6, gift from Dr Robin Brown (Glaxo Wellcome, Stevenage, UK), in frame with the Gal4 DNAbinding domain. The plasmid was linearized within the Trp gene and transformed into the yeast strain Y190. Yeast containing the integrated plasmid and expressing Gal4-DB BRK fusion protein were then transformed with a human breast cDNA library cloned into the HybriZAP pAD-GAL4 vector (Stratagene) according to Clontech Matchmaker protocol. An estimated 1610 6 transformants were screened. Yeast containing interacting proteins were identi®ed by growth on de®ned media lacking leucine, tryptophan and histidine, containing 25 mM 3-aminotriazole (3-AT) and con®rmed by assaying for b-galactosidase activity. Plasmids were rescued from positive yeast colonies and con®rmed by re-introducing it into Y190 cells expressing Gal4-DB BRK fusion protein or a Gal4-DB-p53 fusion protein (non-speci®c control, Clontech). Yeast were then assayed as before. The cDNA inserts of rescued plasmids were sequenced using a Taq Dye Terminator kit (Applied Biosystems) and a ABI 373A automatic sequencer. The T-47D cDNA library was screened as previously described (Mitchell et al., 1994) .
RNA isolation and Northern blots
Total RNA was extracted from cells by the method of Chomczynski and Sacchi (1987) . Poly(A) + RNA was puri®ed using oligo dT sepharose spun columns (Pharmacia). RNA samples were fractionated by electrophoresis through formaldehyde/agarose gels, transferred and crosslinked to Hybond N membranes (Amersham). Random primed probes (Redi-prime, Amersham) were hybridized with the membranes and washed with a ®nal stringency of 0.16SSC, 0.1% SDS at 658C.
Plasmid constructs
The GST BKS fusion protein was made by subcloning the EcoRI ± XhoI BKS cDNAs from the yeast two-hybrid vector into EcoRI ± XhoI cut pGEX 4T-1 (Pharmacia). The amino terminal His tag construct was generated by Pfu polymerase (Stratagene) ampli®cation from BKS cDNAs using the following 5' sense primer CAGGAATTCGCCATGGGAC-GAGGTTCACA TCACCATC ACCATCA CGCCTCTGCC-CTGAGGCCAC and an antisense primer corresponding to bases 445 ± 465 of the BKS cDNA. The ampli®ed product was the cleaved with EcoRI (underlined within primer) and XbaI (cuts within ampli®ed BKS sequence). This 5' tagged EcoRI ± XbaI fragment was then used to replace the 5' end of EcoRI ± XbaI cut BKS cDNAs. For mammalian cell expression vectors, BKS cDNAs were cloned into the EcoRI ± XhoI sites of pCDNA3 (Invitrogen). Site directed mutagenesis was carried out on the BKS cDNAs in pCDNA3 using the QuickChange mutagenesis reagents (Stratagene) and 45mer sense and antisense mutant primers spanning the sequence to be mutated. The cycle parameters were as per the QuickChange protocol.
Cell culture and transfections
With the exception of CAL51 (Gioanni et al., 1990) and the normal breast epithelial cell lines Hb 2 and 4 (Stamps et al., 1994) , all other cell lines were obtained from the American Type Culture Collection and were maintained as recom-mended by the supplier. Preparations of normal mammary epithelial cells were isolated and puri®ed as previously described (Niranjan et al., 1995) . Cell transfections were carried out using the LipofectAMINE reagent according to the manufacturer's instructions (Gibco ± BRL). Cells were plated at a low density (approximately 5610 5 cells/10 cm dish) and allowed to grow for 24 h before transfection. The cells were incubated with DNA (5 mg of plasmid)/lipid mixture for 4 h before being replenished with normal growth media. The cells were harvested 48 h post transfection.
Ni agarose precipitations and immunoblotting
Cells were lysed in RIPA buer (150 mM NaCl, 1% (v/v) NP40, 0.5% (w/v) deoxycholate, 0.1% (w/v) SDS, 50 mM Tris pH 7.5) containing 500 mM sodium vanadate, 16Com-plete protease inhibitor mix (Boehringer Mannheim) and 5 mM imidazole. Hexa His epitope tagged proteins were precipitated by adding 25 ml of Ni NTA agarose (Qiagen) and incubating with the cell lysates for 1 h at 48C. The beads were subsequently washed four times with lysis buer and then eluted in lysis buer containing 200 mM imidazole. For tissue protein extraction, frozen samples were ground to a ®ne powder using a mortar and pestle chilled in a dry ice methanol bath. The frozen, ground tissue samples were then transferred to microfuge tubes and boiled in SDS ± PAGE sample buer. Immunoblots were carried out as previously described . The anti-BRK antibody, ICR100, was generated as previously described (Kamalati et al., 1996) . The anti-phosphotyrosine antibody, PY20, was purchased from Transduction Laboratories. The anti-BKS polyclonal serum was generated by immunizing rabbits with a full length BKS GST fusion protein. The antiserum was subsequently anity puri®ed according to Bar-Peled and Raikhel (1996) .
